Back to top
more

MediWound (MDWD)

(Delayed Data from NSDQ)

$18.53 USD

18.53
53,903

-0.11 (-0.59%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $18.44 -0.09 (-0.49%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's What Could Help MediWound (MDWD) Maintain Its Recent Price Strength

by Zacks Equity Research

MediWound (MDWD) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Zacks Equity Research

MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

MediWound (MDWD) delivered earnings and revenue surprises of 89.23% and 22.39%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

BioHarvest Sciences Inc. (BHST) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

BioHarvest Sciences Inc. (BHST) delivered earnings and revenue surprises of 13.33% and 1.42%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

OptiNose (OPTN) delivered earnings and revenue surprises of -36.49% and 4.58%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Metagenomi (MGX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Metagenomi (MGX) delivered earnings and revenue surprises of -9.68% and 52.83%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

FibroGen (FGEN) delivered earnings and revenue surprises of -633.33% and 71.19%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Theravance Bio (TBPH) delivered earnings and revenue surprises of -54.55% and 4.20%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

MediWound (MDWD) delivered earnings and revenue surprises of 38.98% and 1.53%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

OmniAb, Inc. (OABI) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

OmniAb, Inc. (OABI) delivered earnings and revenue surprises of 7.69% and 18.21%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Esperion Therapeutics (ESPR) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 28.57% and 1.28%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Madrigal (MDGL) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Madrigal (MDGL) delivered earnings and revenue surprises of 34.22% and 1.69%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

MediWound (MDWD) Surges 8.5%: Is This an Indication of Further Gains?

by Zacks Equity Research

MediWound (MDWD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

MediWound (MDWD) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

MediWound (MDWD) delivered earnings and revenue surprises of -104.17% and 27.48%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Omega Therapeutics, Inc. (OMGA) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Omega Therapeutics (OMGA) delivered earnings and revenue surprises of -3.45% and 109.63%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Durect (DRRX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Durect (DRRX) delivered earnings and revenue surprises of 17.65% and 2.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of -56.82% and 26.69%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Xencor (XNCR) delivered earnings and revenue surprises of 27.55% and 38.41%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ardelyx (ARDX) Reports Break-Even Earnings for Q3

by Zacks Equity Research

Ardelyx (ARDX) delivered earnings and revenue surprises of 100% and 13.89%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

MediWound (MDWD) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

MediWound (MDWD) delivered earnings and revenue surprises of -61.90% and 0.18%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of -1.69% and 11.02%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AST SpaceMobile (ASTS) to Post Q2 Earnings: What's in the Cards?

by Zacks Equity Research

AST SpaceMobile (ASTS) is expected to report top-line growth year over year in the second quarter of 2024, backed by healthy demand in several sectors.

Zacks Equity Research

PTC Therapeutics (PTCT) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -16% and 2.82%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Harrow (HROW) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Harrow (HROW) delivered earnings and revenue surprises of 48% and 14.40%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

MediWound (MDWD) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

MediWound (MDWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Strength in Kidney Care Likely to Aid DaVita's (DVA) Q2 Earnings

by Zacks Equity Research

Improvement in RPT and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the second quarter.